Basilea announces launch of antibiotic Zevtera(r)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Basilea announces launch of antibiotic Zevtera(r) (ceftobiprole medocaril) in Germany
  • First commercial launch

BASEL, Switzerland, Dec. 5, 2014 (GLOBE NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that its broad-spectrum antibiotic, Zevtera ® (ceftobiprole medocaril)* has been launched in Germany. The European Centre for Disease Prevention and Control (ECDC) estimates that every year approximately 25,000 people die from antibiotic-resistant healthcare-associated infections in the European Union. 1

The new broad-spectrum antibiotic supports the treatment of bacterial lung infections. Zevtera ® is the only antibiotic monotherapy that is approved in certain European countries 2 for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia (excluding ventilator-associated pneumonia) with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens including Pseudomonas spp . 3

Ronald Scott, Basilea's CEO, stated: "Zevtera's launch in Germany marks an important milestone for Basilea. Antibiotic resistance is a major healthcare threat throughout Europe. We are very pleased to make ceftobiprole available to doctors and their patients, starting in Germany. Ceftobiprole provides physicians and pneumonia patients with a new option to treat severe bacterial infections."

Focus: broad-spectrum antibiotic

Ceftobiprole is a new generation broad-spectrum cephalosporin antibiotic with rapid bactericidal activity against Gram-positive and Gram-negative bacteria associated with pneumonia, including MRSA and Pseudomonas spp. 4 Ceftobiprole is administered intravenously and is the active moiety of the prodrug ceftobiprole medocaril.

David Veitch, Basilea's Chief Commercial Officer, added: "Zevtera provides physicians with a simplified empiric treatment option with its broad-spectrum activity reducing the need for combination treatments. This is an important advance in the empirical treatment of pneumonia." He added: "Post-hoc analyses of phase 3 study data showed a more rapid effect for ceftobiprole as compared with a standard antibiotic combination in the treatment of hospital-acquired pneumonia. An early improvement of patients' overall clinical condition may translate into additional benefits, especially in an intensive care unit setting, such as the potential for earlier mobilization or discharge of the patient to a general ward."

The state of the art in the contemporary treatment of pneumonia was presented at a symposium on "Current antibiotic therapy for pneumonia" at the annual congress of the "German Interdisciplinary Association of Intensive Care and Emergency Medicine" ( Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin , DIVI) in Hamburg, Germany held on December 3-5, 2014.

Pneumonia risk

Pneumonia remains a serious and common infection especially when acquired in a hospital setting. MRSA is an important cause of pneumonia, accounting for 20-40% of hospital-acquired pneumonia. 5 Early initiation of appropriate antibiotic therapy is a key factor for the successful treatment of severe pneumonia. Studies have shown that inappropriate initial therapy of severe infections, including MRSA, are associated with an increased risk of mortality and morbidity, and prolonged hospital stay. 6, 7, 8

Prof. Dr. med. Tobias Welte, Department of Pulmonology, Hannover Medical School (MHH), Germany, commented: "Ceftobiprole provides broad-spectrum Gram-positive and Gram-negative activity including MRSA. MRSA is associated with an increased risk of mortality and morbidity, as well as an increased length of hospital stay. As such, there is a growing need for first-line broad-spectrum antibacterial medicines that also cover resistant bacteria and we hope that ceftobiprole will help fill this gap."

About pneumonia

Pneumonia is a common infection 9, 10 and is generally classified according to the location of the patient when the infection is contracted, since this has a major bearing on the likely type of pathogen causing the disease, the treatment, and the patient's prognosis. Frequent types are community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). CAP is defined as pneumonia acquired outside hospital or extended-care facilities or occurring less than 48 hours after hospital admission. 11 HAP is pneumonia that occurs 48 hours or more after admission to hospital and did not appear to be incubating at the time of admission. HAP is one of the most common infectious diseases acquired in hospitals, affecting 0.5-1.7% of hospitalized patients. 12 The reported all-cause mortality rate for HAP varies widely, ranging from 20-70%. 13, 14 HAP is caused by a wide spectrum of Gram-positive bacteria such as Staphylococcus aureus , particularly MRSA, and Gram-negative bacteria.

About MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) is a Gram-positive bacterium and an important cause of pneumonia, accounting for 20-40% of HAP cases. 5 MRSA rates are above 25% in seven of the 30 countries of the European Union (EU) and the European Economic Area reporting to the European Centre for Disease Prevention and Control (ECDC). Based on these figures and generally high MRSA rates, the ECDC considers MRSA a public health priority. 15 The ECDC estimates that approximately 4 million patients acquire a healthcare-associated infection in the EU every year, resulting in at least 37,000 deaths, of which 25,000 are currently estimated to be due to the most common resistant bacteria, i.e. Staphylococcus aureus or Pseudomonas aeruginosa . 1

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to develop and commercialize innovative pharmaceutical products to meet the significant medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com .

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Media Relations Investor Relations
Peer Nils Schröder, PhD
Head Public Relations &
Corporate Communications
+41 61 606 1102
media_relations@basilea.com
Barbara Zink, PhD, MBA
Head Corporate Development

+41 61 606 1233
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com .

References

* European brand name Zevtera ® or Mabelio ® , depending on the country

1 European Centre for Disease Prevention and Control. Antimicrobial resistance and healthcare-associated infections. http://www.ecdc.europa.eu/en/activities/disea...ramme.aspx [Accessed November 28, 2014]

2 Following approval under the European decentralized procedure, ceftobiprole has received national licenses in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Norway, Spain, Sweden and the United Kingdom; reimbursement and pricing authorization in several countries including Spain is ongoing

3 Summary of Product Characteristics; http://www.mhra.gov.uk/home/groups/spcpil/doc...361819.pdf
[Accessed December 4, 2014]

4 Y. Y. Syed. Ceftobiprole medocaril: A review of its use in patients with hospital- or community-acquired pneumonia. Drugs 2014 (74), 1523-1542

5 E. Rubinstein et al. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clinical Infectious Diseases 2008 (46), Suppl 5, S378-S385

6 T. Welte, M. W. Pletz. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. International Journal of Antimicrobial Agents 2010 (36), 391-400

7 A. F. Shorr, S. T. Micek, M. H. Kollef. Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications. Critical Care Medicine 2008 (36), 2335-2340

8 A. P. MacGowan. Clinical implications of antimicrobial resistance for therapy. Journal of Antimicrobial Chemotherapy 2008 (62), Suppl. 2, ii105-ii114

9 M. R. Loebinger, R. Wilson. Pneumonia. Medicine 2012 (40), 329-334

10 White Book. http://www.erswhitebook.org/chapters/acute-lo...pneumonia/
[Accessed September 30, 2014]

11 G. B. Nair, M. S. Niederman. Community-acquired pneumonia: an unfinished battle. Medical Clinics of North America 2011 (95), 1143-1161

12 R. Masterton et al. Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. Journal of Antimicrobial Chemotherapy 2007 (60), 206-213

13 American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2005 (171), 388-416

14 M. H. Kollef et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005 (128), 3854-3862

15 European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC 2013

Press release (PDF) http://hugin.info/134390/R/1877434/661714.pdf

HUG#1877434

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 187

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 5

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
DemandTec Leads the Pack in Retail Pricing Arena

Updated Category News Views 46

DemandTec's Climb to Retail Pricing Stardom The news hitting the streets is that DemandTec's carved out a top spot in QKS Group's SPARK Matrix™ for Intelligent Retail Pricing & Promotion Optimization for 2026. In an industry filled with slick operators and gimmicks, it takes some real chops to stand out. They've clinched this position by rolling out a platform that ties...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 131

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 59

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 0

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 35

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
DarioHealth's New Research Tackles Healthcare Cost Estimation

Updated Category News Views 67

Unpacking Dario's Bold Surgical Strike at ISPOR Europe Alright, folks, DarioHealth is shaking up the stage with their new methodology that could very well carve a new path in how we size up digital healthcare savings. Presented at ISPOR Europe 2026, Dario's tactic bypasses the sluggish wait on medical claims data, instead offering an evidence-driven peek at potential...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 117

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Plumas Bancorp Increases Shareholder Value with Dividend

Updated Category News Views 100

Plumas Bancorp Announces Quarterly Cash Dividend Plumas Bancorp (Nasdaq: PLBC), the parent company of Plumas Bank, has recently made an important announcement regarding its financial strategy. The Board of Directors has declared a regular quarterly cash dividend of $0.30 per share on common stock, as a testament to the company's ongoing commitment to delivering value to...

Continue Reading
DTE Energy's Junior Subordinated Debentures Offer: Key Insights

Updated Category News Views 168

DTE Energy's Junior Subordinated Debentures Introduction DTE Energy Company (NYSE: DTE) has made a significant announcement regarding its financial strategies through the pricing of its 2025 Series H 6.25% Junior Subordinated Debentures. This offering, valued at $600 million in aggregate principal, is designed for various financial maneuvers that could solidify DTE's...

Continue Reading
Key Insights on SCOR's Share Capital and Voting Rights Details

Updated Category News Views 294

Understanding SCOR's Recent Share Capital Declaration On a notable date, SCOR made a significant announcement regarding its share capital. The communication was essential for understanding the current status of total shares and voting rights. As a leading global reinsurer, SCOR's declarations provide crucial insights into its financial health and operational metrics....

Continue Reading
Enthusiast Gaming's Record-Breaking Spectacle at Luminosity Event

Updated Category News Views 100

Enthusiast Gaming's Luminosity Invitational Shines Bright Enthusiast Gaming Holdings Inc. ('Enthusiast Gaming' or the 'Company'), a dynamic leader in the gaming and media sector, has made waves recently with its spectacular Luminosity Invitational: Back 2 School. This thrilling Super Smash Bros Ultimate event drew in a staggering estimate of over 400,000 unique online...

Continue Reading
UAB Kvartalas Closes Subscription Early for Latest Bonds

Updated Category News Views 128

UAB Kvartalas Closes Subscription for 4th Tranche of Bonds UAB "Kvartalas", a legal entity committed to facilitating growth and innovation, has made a significant announcement regarding its bond issuance process. The company, registered with the legal code 305475438, has its headquarters situated at Jogailos St. 4, Vilnius, Republic of Lithuania. In response to...

Continue Reading